검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | TCR-T cells (MDG1015) |
Overview Company | Medigene AG |
Overview Modality | CGT |
Overview Target | Epithelial Ovarian Cancer |
Overview Indication | Epithelial Ovarian Cancer; Gastro-esophageal Junction Cancer |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | CAR-T), natural killer (NK) cells, and other emerging cellular therapies such as TCR-T, cytokine-induced killer (CIK) cells, and γδ T cells-in the context of ovarian cancer |
MoA Biomarker | biomarkers, tumor microenvironment profiling, and personalized treatment selection is explored as a means to |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Adoptive cell therapies in solid tumors: current clinical landscape, challenges, and future directions.. Adoptive cell therapy (ACT) has emerged as a transformative strategy in cancer immunotherapy, offering durable clinical benefit in hematologic malignancies and expanding therapeutic potential in solid tumors. However, the translation of ACT to solid malignancies remains constrained by biologica… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 11.8% |
Clinical ORR | 11.8% |
Clinical PFS | 2.8 |
Clinical OS | 20.4 |
Clinical Result source | ClinicalTrials.gov NCT01950390 |
Clinical Data Tier / Score | A · 43 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | TCR-T cells (MDG1015) |
Overview Company | Medigene AG |
Overview Modality | CGT |
Overview Target | Epithelial Ovarian Cancer |
Overview Indication | Epithelial Ovarian Cancer; Gastro-esophageal Junction Cancer |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | CAR-T), natural killer (NK) cells, and other emerging cellular therapies such as TCR-T, cytokine-induced killer (CIK) cells, and γδ T cells-in the context of ovarian cancer |
MoA Biomarker | biomarkers, tumor microenvironment profiling, and personalized treatment selection is explored as a means to |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Adoptive cell therapies in solid tumors: current clinical landscape, challenges, and future directions.. Adoptive cell therapy (ACT) has emerged as a transformative strategy in cancer immunotherapy, offering durable clinical benefit in hematologic malignancies and expanding therapeutic potential in solid tumors. However, the translation of ACT to solid malignancies remains constrained by biologica… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 11.8% |
Clinical ORR | 11.8% |
Clinical PFS | 2.8 |
Clinical OS | 20.4 |
Clinical Result source | ClinicalTrials.gov NCT01950390 |
Clinical Data Tier / Score | A · 43 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교